Category Archives: Dr. Randy Vogenberg

Dr. Randy Vogenberg, Trends

A Call to Action to Address Burden of Unintended Pregnancies in Plans’ Benefit Design

Posted on by John Santilli

Benefit Design – A Call to Action to Address Burden of Unintended Pregnancies in Plans’ Benefit Design F. Randy Vogenberg, PhD, RPh Partner, Access Market Intelligence, Greenville, SC Adjunct Professor of Pharmacy Administration, Presbyterian College School of Pharmacy, Clinton, SC Adjunct Instructor, Outcomes and Health Policy, University of Illinois at Chicago College of Pharmacy Originally […]

Continue reading →
Dr. Randy Vogenberg

Seeking Value: Managing Specialty Medications and Medication Adherence

Posted on by John Santilli

Amid the constant change churning the health care marketplace, employers have the opportunity to use value-based tactics to get more for their health benefits, including pharmaceutical spending that is currently the biggest driver of rising health care costs. That message was echoed by all four speakers at the Alliance Learning Circle on “Doses and Dollars: […]

Continue reading →
Affordable Care Act, Dr. Randy Vogenberg, John Santilli, Market Intelligence, Trends

Key Strategic Trends that Impact Healthcare Decision-Making and Stakeholder Roles in the New Marketplace

Posted on by aprilgregory

By John Santilli, MBA, and F. Randy Vogenberg, PhD, RPh After the passage of the Affordable Care Act (ACA) in 2010, market changes beyond those already in play began to emerge. Traditional roles, responsibilities, and authority could now be tested or altered as a result of some sections of the ACA. One result is that […]

Continue reading →
Dr. Randy Vogenberg, Market Intelligence

Biosimilar Confusion and Insights

Posted on by Dr. Randy

Since Virginia became the first state in May 2013 to enact legislation regulating a pharmacist’s substitution of an interchangeable biologic drug for a prescribed reference biologic drug, there has not been much activity or clarity on the issue. This issue continues to pit manufacturer versus manufacturer, and other stakeholders against each other in the policy […]

Continue reading →
Dr. Randy Vogenberg

The Changing Roles of P&T Committees: A Look Back at the Last Decade and a Look Forward to 2020

Posted on by Dr. Randy

Originally published at Pharmacy & Therapeutics – November 2014   http://www.nxtbook.com/nxtbooks/medimedia/pt_201411/src/forms/PT_November_2014_iframe_live.html#/38 Market and regulatory changes in the last 10 years, as well as the Affordable Care Act, have resulted in significant modifications to health care delivery models.  Traditionally, P&T committees limited the impact of their decisions to the populations associated with their hospital or health plan; […]

Continue reading →